We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The companies will also partner on developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of serious multidrug-resistant infections caused by Acinetobacter baumannii.
According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set to grow from $1.24 billion in 2015 to more than $1.71 billion in 2022.